These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10989244)

  • 21. [Hormone replacement therapy with a transdermal estradiol gel and oral micronized progesterone. Effect on menopausal symptoms and lipid metabolism].
    Giuliani A; Concin H; Wieser F; Boritsch J; Wilfert H; Gruber D; Urdl W
    Wien Klin Wochenschr; 2000 Jul; 112(14):629-33. PubMed ID: 11008325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative study of the acceptability of a new estradiol Tx 11323 (A) gel and a transdermal matrix system].
    Gelas B; Thébault J; Roux I; Herbrecht F; Zartarian M
    Contracept Fertil Sex; 1997 Jun; 25(6):470-4. PubMed ID: 9280552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New trends in transdermal technologies: development of the skin patch, Menorest.
    Marty JP
    Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S17-20. PubMed ID: 8666122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thoughts on individualizing hormone replacement therapy based on the postmenopausal health disparities study data.
    Gavaler JS
    J Womens Health (Larchmt); 2003 Oct; 12(8):757-68. PubMed ID: 14588126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms.
    Mizunuma H
    Climacteric; 2011 Oct; 14(5):581-9. PubMed ID: 21848497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
    Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
    Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of transdermal with oral hormone substitution: a multicenter study with a new matrix patch].
    Sajtos B; Herold J; Winkler UH; Schindler AE
    Zentralbl Gynakol; 1995; 117(10):524-30. PubMed ID: 7491835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When is it safe to switch from oral contraceptives to hormonal replacement therapy?
    Castracane VD; Gimpel T; Goldzieher JW
    Contraception; 1995 Dec; 52(6):371-6. PubMed ID: 8749601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
    Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
    Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
    Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J; Thebault J
    Maturitas; 1996 Nov; 25(3):175-85. PubMed ID: 8981334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [17 beta-estradiol. as a patch. An elixir of youth as a prescription for the menopausal woman].
    Taeron C
    Rev Infirm; 2002 Mar; (79):45-7. PubMed ID: 11979678
    [No Abstract]   [Full Text] [Related]  

  • 32. Can climacteric women self-adjust therapeutic estrogen doses using symptoms as markers?
    Vihtamäki T; Tuimala R
    Maturitas; 1998 Jan; 28(3):199-203. PubMed ID: 9571594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effectiveness and tolerance of pulsed estrogen therapy in the treatment of menopausal symptoms. Results of a Polish multicenter study].
    Szamatowicz M
    Ginekol Pol; 2005 Mar; 76(3):245-51. PubMed ID: 16018146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skin reactions to transdermal estrogen replacement therapy in a tropical climate.
    de Cetina TC; Reyes LP
    Int J Gynaecol Obstet; 1999 Jan; 64(1):71-2. PubMed ID: 10190675
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of chronic daily oral administration of 17 beta-oestradiol and norethisterone on the isoforms of serum gonadotrophins in post-menopausal women.
    Wide L; Naessén T; Phillips DJ
    Clin Endocrinol (Oxf); 1995 Jan; 42(1):59-64. PubMed ID: 7889633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal estradiol and lipid profile: effects on a specific group of Brazilian postmenopausal women.
    Callejon DR; Rios DR; Franceschini SA; Toloi MR
    Arq Bras Cardiol; 2009 Dec; 93(6):571-5, 617-22. PubMed ID: 20379635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum concentrations of 17beta-estradiol and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women.
    Brennan JJ; Lu Z; Whitman M; Stafiniak P; van der Hoop RG
    Ther Drug Monit; 2001 Apr; 23(2):134-8. PubMed ID: 11294513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
    Rohr UD; Nauert C; Stehle B
    Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Percutaneous 17 beta-estradiol replacement therapy in hypertensive postmenopausal women.
    Osório-Wender MC; Vitola D; Spritzer PM
    Braz J Med Biol Res; 1997 Sep; 30(9):1047-53. PubMed ID: 9458963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.